Prescribing information



Change lives in myelofibrosis with JAKAVI1–3

JAKAVI (ruxolitinib) is the only licensed oral JAK1 and JAK2 inhibitor targeted therapy approved to treat adult patients with myelofibrosis (MF).1


JAKAVI (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis.1


Jakavi (ruxolitinib) logo


MF, myelofibrosis.


  1. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
  2. Verstovsek S, et al. N Engl J Med. 2012;366:799–807.
  3. Harrison C, et al. N Engl J Med. 2012;366:787–798.
HCP20-C024 June 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]